BCR-ABL promotes the frequency of mutagenic single-strand annealing DNA repair

被引:46
作者
Fernandes, Margret S. [1 ,2 ,3 ]
Reddy, Mamatha M. [1 ,2 ,3 ]
Gonneville, Jeffrey R. [1 ]
DeRoo, Scott C. [1 ]
Podar, Klaus [1 ,2 ,3 ]
Griffin, James D. [1 ,2 ,3 ]
Weinstock, David M. [1 ,2 ,3 ]
Sattler, Martin [1 ,2 ,3 ]
机构
[1] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA
[2] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA
[3] Harvard Univ, Sch Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
TYROSINE KINASE INHIBITOR; BREAK REPAIR; V(D)J RECOMBINATION; HOMOLOGOUS REPAIR; BCR/ABL; RESISTANCE; TRANSFORMATION; IMATINIB; PATHWAY; CELLS;
D O I
10.1182/blood-2008-07-172148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Intracellular oxidative stress in cells transformed by the BCR-ABL oncogene is associated with increased DNA double-strand breaks. Imprecise repair of these breaks can result in the accumulation of mutations, leading to therapy-related drug resistance and disease progression. Using several BCR-ABL model systems, we found that BCR-ABL specifically promotes the repair of double-strand breaks through single-strand annealing (SSA), a mutagenic pathway that involves sequence repeats. Moreover, our results suggest that mutagenic SSA repair can be regulated through the interplay between BCR-ABL and extrinsic growth factors. Increased SSA activity required Y177 in BCR-ABL, as well as a functional PI3K and Ras pathway downstream of this site. Furthermore, our data hint at a common pathway for DSB repair whereby BCR-ABL, Tel-ABL, Tel-PDGFR, FLT3-ITD, and Jak2V617F all increase mutagenic repair. This increase in SSA may not be sufficiently suppressed by tyrosine kinase inhibitors in the stromal microenvironment. Therefore, drugs that target growth factor receptor signaling represent potential therapeutic agents to combat tyrosine kinase-induced genomic instability. (Blood. 2009; 114:1813-1819)
引用
收藏
页码:1813 / 1819
页数:7
相关论文
共 45 条
[1]   DIFFERENTIAL COMPLEMENTATION OF BCR-ABL POINT MUTANTS WITH C-MYC [J].
AFAR, DEH ;
GOGA, A ;
MCLAUGHLIN, J ;
WITTE, ON ;
SAWYERS, CL .
SCIENCE, 1994, 264 (5157) :424-426
[2]   Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL [J].
Azam, M ;
Latek, RR ;
Daley, GQ .
CELL, 2003, 112 (06) :831-843
[3]   Targeting mutated tyrosine kinases in the therapy of myeloid leukaemias [J].
Banerji, L ;
Sattler, M .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2004, 8 (03) :221-239
[4]   Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair [J].
Bennardo, Nicole ;
Cheng, Anita ;
Huang, Nick ;
Stark, Jeremy M. .
PLOS GENETICS, 2008, 4 (06)
[5]   p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation [J].
Canitrot, Y ;
Falinski, R ;
Louat, T ;
Laurent, G ;
Cazaux, C ;
Hoffmann, JS ;
Lautier, D ;
Skorski, T .
BLOOD, 2003, 102 (07) :2632-2637
[6]   CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins [J].
Carroll, M ;
OhnoJones, S ;
Tamura, S ;
Buchdunger, E ;
Zimmermann, J ;
Lydon, NB ;
Gilliland, DG ;
Druker, BJ .
BLOOD, 1997, 90 (12) :4947-4952
[7]   BCR-tyrosine 177 plays an essential role in Ras and Akt activation and in human hematopoietic progenitor transformation in chronic myelogenous leukemia [J].
Chu, Su ;
Li, Liang ;
Singh, Harjeet ;
Bhatia, Ravi .
CANCER RESEARCH, 2007, 67 (14) :7045-7053
[8]   BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair [J].
Cramer, Kimberly ;
Nieborowska-Skorska, Margaret ;
Koptyra, Mateusz ;
Slupianek, Artur ;
Penserga, Emir Tyrone P. ;
Eaves, Connie J. ;
Aulitzky, Walter ;
Skorski, Tomasz .
CANCER RESEARCH, 2008, 68 (17) :6884-6888
[9]   BCR-ABL down-regulates the DNA repair protein DNA-PKcs [J].
Deutsch, E ;
Dugray, A ;
AbdulKarim, B ;
Marangoni, E ;
Maggiorella, L ;
Vaganay, S ;
M'Kacher, R ;
Rasy, SD ;
Eschwege, F ;
Vainchenker, W ;
Turhan, AG ;
Bourhis, J .
BLOOD, 2001, 97 (07) :2084-2090
[10]   BCR/ABL translocates to the nucleus and disrupts an ATR-dependent intra-S phase checkpoint [J].
Dierov, J ;
Dierova, R ;
Carroll, M .
CANCER CELL, 2004, 5 (03) :275-285